CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative ...

Why our beauty team swears by green colour correctors on no makeup days. Colour correctors arrive in an array of hues, from ...

Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...

Annual Meeting took place in Toronto, Canada, July 11-15, with our top coverage including the hot topics of combating ...

H.C. Wainwright analyst Douglas Tsao initiated coverage of Arcutis Biotherapeutics (ARQT) with a Buy rating and $19 price target The firm ...

The US FDA has approved Vtama 1% cream for the topical treatment of atopic dermatitis in adult and pediatric patients aged 2 years and older.

Many eye ointments can help manage and treat symptoms of eye conditions like styes, pink eye, and other infections. When using eye ointments, it’s important to follow the directions. Eye ...

doi:10.1136/bmj.j1415 National Eczema Association. Incyte announces U.S. FDA Approval of Opzelura (ruxolitinib) cream, a topical JAK inhibitor, for the treatment of atopic dermatitis (AD). Food and ...

The US Food and Drug Administration (FDA) has approved Vtama (tapinarof) cream 1%, an aryl hydrocarbon receptor agonist, for the topical treatment of atopic dermatitis in adults and children aged 2 ...